Chandrayee Ghosh

Dr. Chandrayee Ghosh

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in Thyroid®
Verified
Journal Article
Closed access
VGViswanath Gunda
Viswanath Gunda
Chandrayee GhoshChandrayee Ghosh
Chandrayee Ghosh
JHJiangnan Hu
Jiangnan Hu
LZLisa Zhang
Lisa Zhang
YZYa Qin Zhang
Ya Qin Zhang
EKElectron Kebebew
Electron Kebebew
Background: Anaplastic thyroid cancer (ATC) is uniformly lethal. BRAF V600E mutation is present in 45% of patients with ATC. Targeted therapy with combined BRAF and MEK inhibition in BRAF V600E -mutant ATC can be effective, but acquired resistance is common because this combination targets the same pathway. Drug matrix screening, in BRAF V600E ATC cells, of highly active compounds in combination with BRAF inhibition showed multitargeting tyrosine kinase inhibitors (MTKIs) had the highest synergistic/additive activity. Thus, we hypothesized that the combination of BRAF V600E inhibition and an MTKI is more effective than a single drug or combined BRAF and MEK inhibition in BRAF V600E -mutant ATC. We evaluated the effect of BRAF V600E inhibitors in combination with the MTKI axitinib and its mechanism(s) of action. Methods: We evaluated the effects of BRAF V600E inhibitors and axitinib alone and in combination in in vitro and in vivo models of BRAF V600E -mutant and wild-type ATC. Results: The combination of axitinib and BRAF V600E inhibitors (dabrafenib and PLX4720) showed an additive effect on inhibiting cell proliferation based on the Chou–Talalay algorithm in BRAF V600E -mutant ATC cell lines. This combination also significantly inhibited cell invasion and migration ( p < 0.001) compared with the control. Dabrafenib and PLX4720 arrested ATC cells in the G0/G1 phase. Axitinib arrested ATC cells in the G2/M phase by decreasing phosphorylation of aurora kinase B (Thr232) and histone H3 (Ser10) proteins and by upregulating the c-JUN signaling pathway. The combination of BRAF inhibition and axitinib significantly inhibited tumor growth and was associated with improved survival in an orthotopic ATC model. Conclusions: The novel combination of axitinib and BRAF V600E inhibition enhanced anticancer activity in in vitro and in vivo models of BRAF V600E -mutant ATC. This combination may have clinical utility in BRAF V600E -mutant ATC that is refractory to current standard therapy, namely combined BRAF and MEK inhibition.

Verified
Journal Article
Open access
PDF file
TSTae-Yon Sung
Tae-Yon Sung
WMWilson Alobuia M.D
Wilson Alobuia M.D
MTMonica Varun Tyagi
Monica Varun Tyagi
Chandrayee GhoshChandrayee Ghosh
Chandrayee Ghosh
EKElectron Kebebew
Electron Kebebew
The aim of this study is to determine the accuracy of adrenal vein sampling (AVS) with and without adrenocorticotropic hormone (ACTH) stimulation to distinguish between unilateral and bilateral primary hyperaldosteronism (PA). Retrospective analysis of a prospective database from a referral center between 1984 and 2009, 76 patients had simultaneous cannulation of bilateral adrenal veins and AVS with and without ACTH stimulation. All patients had adrenalectomies. The selectivity index (SI, cut-off value ≥2) was used for confirmation of successful cannulation of the adrenal vein. The lateralization index (LI, cut-off value >2 and >4) was used for distinguishing between unilateral and bilateral PA. The SI ratio was higher with ACTH stimulation compared to without for the right adrenal vein (p = 0.027). The LI > 2 ratio was higher with ACTH stimulation compared to without (p = 0.007). For the LI > 4 ratio, there was no difference between with and without ACTH stimulation (p = 0.239). However, for a LI > 4, 7 patients (9.2%) were not lateralized with ACTH stimulation, but they did lateralize without ACTH stimulation. AVS with ACTH stimulation is associated with a higher SI ratio compared to AVS without ACTH stimulation. However, when using LI > 4 for AVS, samples without ACTH stimulation should also be included to detect a subset of patients with unilateral disease that are not detected with ACTH stimulation.

19 August 2025 in Cancer Letters
Verified
Journal Article
Closed access
Chandrayee GhoshChandrayee Ghosh
Chandrayee Ghosh
TKTejinder Pal Khaket
Tejinder Pal Khaket
VGViswanath Gunda
Viswanath Gunda
ZYZhongyue Yang
Zhongyue Yang
JHJiangnan Hu
Jiangnan Hu
EKElectron Kebebew
Electron Kebebew

24 February 2024
Verified
Book Chapter
Closed access
Chandrayee GhoshChandrayee Ghosh
Chandrayee Ghosh
JHJiangnan Hu
Jiangnan Hu

27 November 2025 in Cancer Letters
Verified
Journal Article
Closed access
Chandrayee GhoshChandrayee Ghosh
Chandrayee Ghosh
TKTejinder Pal Khaket
Tejinder Pal Khaket
VGViswanath Gunda
Viswanath Gunda
ZYZhongyue Yang
Zhongyue Yang
JHJiangnan Hu
Jiangnan Hu
EKElectron Kebebew
Electron Kebebew